About This Deal

Gilead Sciences acquired MYR GmbH for ~EUR 1.3 billion (~$1.6 billion), a transaction announced in March 2021.

Acquired the German biotechnology company for its chronic hepatitis delta virus (HDV) treatment Hepcludex (bulevirtide), conditionally approved by the EMA. Aggregate consideration of EUR 1.3 billion (~$1.6 billion), including ~EUR 1.0 billion (~$1.2 billion) paid on closing plus contingent consideration.

Acquired the German biotechnology company for its chronic hepatitis delta virus (HDV) treatment Hepcludex (bulevirtide), conditionally approved by the EMA. Aggregate consideration of EUR 1.3 billion (~$1.6 billion), including ~EUR 1.0 billion (~$1.2 billion) paid on closing plus contingent consideration.

Deal Terms

Acquirer
Gilead Sciences
Target
MYR GmbH
Value
~EUR 1.3 billion (~$1.6 billion)
Date
March 2021
Type
Full acquisition
Status
Completed

Transaction Details

Announced
March 4, 2021

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.